Calidi Biotherapeutics, Inc. (CLDI)
$1.32+$0.02 (+1.54%) Today
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 8 | 85,000 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
25 Form 4 filings on record, the earliest from Oct 15, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| George Peoples - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 4,000 | $0.00 | - | |
| Scott Leftwich - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 4,000 | $0.00 | - | |
| Alan R. Stewart - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 4,000 | $0.00 | - | |
| Andrew C. Jackson - Officer | Grant or award | Stock Options (right to buy) | 14,000 | - | - | |
| James A. Schoeneck - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 5,000 | $0.00 | - | |
| Eric E. Poma - Officer | Grant or award | Stock Options (right to buy) | 32,000 | - | - | |
| Santidrian Antonio Fernandez - Officer | Grant or award | Stock Options (right to buy) | 16,000 | - | - | |
| Corazon (Corsee) D. Sanders - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 6,000 | $0.00 | - | |
| Allan Camaisa - Director | Open-market sale | Common Stock | 850 | $23.28 | $1K | |
| Eric E. Poma - Officer | Grant or award | Stock Options (right to buy) | 10,000 | - | - | |
| Andrew C. Jackson - Officer | Grant or award | Stock Options (right to buy) | 30,000 | - | - | |
| Santidrian Antonio Fernandez - Officer | Grant or award | Stock Options (right to buy) | 35,000 | - | - | |
| James A. Schoeneck - Director | Open-market purchase | Common Stock | 75,000 | $32.00 | $150K | |
| James A. Schoeneck - Director | Open-market purchase | Warrant (right to buy) | 75,000 | - | - | |
| Eric E. Poma - Officer | Open-market purchase | Common Stock | 25,000 | $32.00 | $50K | |
| Eric E. Poma - Officer | Open-market purchase | Warrant (right to buy) | 25,000 | - | - | |
| Scott Leftwich - Director | Open-market purchase | Common Stock | 125,000 | $32.00 | $250K | |
| Scott Leftwich - Director | Open-market purchase | Warrant (right to buy) | 125,000 | - | - | |
| Andrew C. Jackson - Officer | Open-market purchase | Common Stock | 2,500 | $32.00 | $5K | |
| Andrew C. Jackson - Officer | Open-market purchase | Warrant (right to buy) | 2,500 | - | - | |
| James A. Schoeneck - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 164,493 | $0.00 | - | |
| George Peoples - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 137,078 | $0.00 | - | |
| Scott Leftwich - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 137,078 | $0.00 | - | |
| Alan R. Stewart - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 137,078 | $0.00 | - | |
| Allan Camaisa - Officer | Open-market sale | Common Stock | 10,000 | $311.04 | $16K | |
| Scott Leftwich - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 20,217 | - | - | |
| George Peoples - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 20,217 | - | - | |
| Alan R. Stewart - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 20,217 | - | - | |
| James A. Schoeneck - Director | Grant or award | Non-Qualified Stock Options (right to buy) | 20,217 | - | - |
Calidi Biotherapeutics, Inc. (CLDI) had 8 insider filings in the last 90 days, with the most recent on 2026-08-19. The full record for CLDI runs to 25 Form 4 filings, the earliest from 2024-10-15. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CLDI were filed in the last 90 days. 8 purchases are on record for this company.
No insider sales of CLDI were filed in the last 90 days. 2 sales are on record for this company.
This page tracks CLDI Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CLDI to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
